File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Trends in lipid-modifying agent use in 83 countries

TitleTrends in lipid-modifying agent use in 83 countries
Authors
KeywordsLipid-modifying agents
Drug utilization
Global healthSales
Pharmacoepidemiology
Issue Date2021
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis
Citation
Atherosclerosis, 2021, v. 328, p. 44-51 How to Cite?
AbstractBackground and aims: Lipid-modifying agents (LMAs) are increasingly used to reduce lipid levels and prevent cardiovascular events but the magnitude of their consumption in different world regions is unknown. We aimed to describe recent global trends in LMA consumption and to explore the relationship between country-level LMA consumption and cholesterol concentrations. Methods: This cross-sectional and ecological study used monthly pharmaceutical sales data from January 2008 to December 2018 for 83 countries from the IQVIA Multinational Integrated Data Analysis System and total and non-high-density lipoprotein (non-HDL) cholesterol concentrations from the NCD Risk Factor Collaboration. Compound annual growth rate (CAGR) was used to assess changes in LMA consumption over time. Results: From 2008 to 2018, use of LMAs increased from 7468 to 11,197 standard units per 1000 inhabitants per year (CAGR 4.13%). An estimated 173 million people used LMAs in 2018. Statins were the most used class of LMA and their market share increased in 75% of countries between 2008 and 2018. From 2013 to 2018, consumption of low-density lipoprotein lowering therapies increased (statins 3.99%; ezetimibe 4.01%; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 104.47%). Limited evidence supports a clear relationship between country-level changes in LMA consumption and mean total and non-HDL cholesterol concentrations in 2008 versus 2018. Conclusions: Since 2008, global access to LMAs, especially statins, has improved. In line with international lipid guideline recommendations, recent trends indicate growth in the use of statins, ezetimibe, and PCSK9 inhibitors. Country-level patterns of LMA use and total and non-HDL cholesterol varied considerably.
DescriptionHybrid open access
Persistent Identifierhttp://hdl.handle.net/10722/301277
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.461
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBLAIS, JE-
dc.contributor.authorWEI, Y-
dc.contributor.authorYap, KWK-
dc.contributor.authorAlwafi, H-
dc.contributor.authorMa, TT-
dc.contributor.authorBrauer, R-
dc.contributor.authorLau, WCY-
dc.contributor.authorMan, KKC-
dc.contributor.authorSiu, CW-
dc.contributor.authorTan, KCB-
dc.contributor.authorWong, ICK-
dc.contributor.authorWei, L-
dc.contributor.authorChan, EW-
dc.date.accessioned2021-07-27T08:08:45Z-
dc.date.available2021-07-27T08:08:45Z-
dc.date.issued2021-
dc.identifier.citationAtherosclerosis, 2021, v. 328, p. 44-51-
dc.identifier.issn0021-9150-
dc.identifier.urihttp://hdl.handle.net/10722/301277-
dc.descriptionHybrid open access-
dc.description.abstractBackground and aims: Lipid-modifying agents (LMAs) are increasingly used to reduce lipid levels and prevent cardiovascular events but the magnitude of their consumption in different world regions is unknown. We aimed to describe recent global trends in LMA consumption and to explore the relationship between country-level LMA consumption and cholesterol concentrations. Methods: This cross-sectional and ecological study used monthly pharmaceutical sales data from January 2008 to December 2018 for 83 countries from the IQVIA Multinational Integrated Data Analysis System and total and non-high-density lipoprotein (non-HDL) cholesterol concentrations from the NCD Risk Factor Collaboration. Compound annual growth rate (CAGR) was used to assess changes in LMA consumption over time. Results: From 2008 to 2018, use of LMAs increased from 7468 to 11,197 standard units per 1000 inhabitants per year (CAGR 4.13%). An estimated 173 million people used LMAs in 2018. Statins were the most used class of LMA and their market share increased in 75% of countries between 2008 and 2018. From 2013 to 2018, consumption of low-density lipoprotein lowering therapies increased (statins 3.99%; ezetimibe 4.01%; proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 104.47%). Limited evidence supports a clear relationship between country-level changes in LMA consumption and mean total and non-HDL cholesterol concentrations in 2008 versus 2018. Conclusions: Since 2008, global access to LMAs, especially statins, has improved. In line with international lipid guideline recommendations, recent trends indicate growth in the use of statins, ezetimibe, and PCSK9 inhibitors. Country-level patterns of LMA use and total and non-HDL cholesterol varied considerably.-
dc.languageeng-
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis-
dc.relation.ispartofAtherosclerosis-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectLipid-modifying agents-
dc.subjectDrug utilization-
dc.subjectGlobal healthSales-
dc.subjectPharmacoepidemiology-
dc.titleTrends in lipid-modifying agent use in 83 countries-
dc.typeArticle-
dc.identifier.emailLau, WCY: wallisy@hku.hk-
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.authoritySiu, CW=rp00534-
dc.identifier.authorityTan, KCB=rp00402-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityChan, EW=rp01587-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.atherosclerosis.2021.05.016-
dc.identifier.pmid34091069-
dc.identifier.scopuseid_2-s2.0-85107354531-
dc.identifier.hkuros323782-
dc.identifier.volume328-
dc.identifier.spage44-
dc.identifier.epage51-
dc.identifier.isiWOS:000667985500006-
dc.publisher.placeIreland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats